Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
← catalyst calendarNCT04824092 · readout in 13 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
899actual
Sites
307
Countries
Argentina, Australia, Austria +26
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-05-11 | actual | When the study began enrolling |
| Primary completion | 2026-09-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-01 | estimated | The whole study's end, after follow-up |
| First posted | 2021-04-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diffuse Large B-cell Lymphoma
Interventions
- Drug: Tafasitamab — also filed as Monjuvi
- Drug: Lenalidomide
- Drug: Rituximab
- Drug: Cyclophosphamide
- Drug: Doxorubicin
- Drug: Vincristine
- Drug: Prednisone
- Drug: Tafasitamab placebo
- Drug: Lenalidomide placebo
Primary outcome
what the primary-completion date above is the date OFPFS-INV
measured Time from date of randomization until Progressive Disease or death from any cause. In this trial, the primary endpoint is PFS as assessed by the investigator (up to 43 months)
Publications
- PMID 42217458 — linked by the registry
- PMID 40993016 — linked by the registry
- PMID 39319495 — linked by the registry
- PMID 37369099 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed